Novartis Forecast, price target & analysts
Novartis Target price 2025 - Analyst rating & recommendation
Novartis Classifications & Recommendation:
Novartis Price Target
| Target Price | CHF103.65 |
| Price | CHF98.15 |
| Potential | 5.61% |
| Number of Estimates | 23 |
| 23 Analysts have issued a price target Novartis 2026 . The average Novartis target price is CHF103.65. This is 5.61% higher than the current stock price. The highest price target is CHF124.40 26.74% , the lowest is CHF81.12 17.35% . | |
| A rating was issued by 28 analysts: 6 Analysts recommend Novartis to buy, 18 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2026 of 5.61% . Most analysts recommend the Novartis stock at Hold. |
Sales and Margin forecast 2025, 2026 to 2029
23 Analysts have issued a sales forecast Novartis 2025 . The average Novartis sales estimate is CHF47.4b . This is 6.88% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF49.2b 11.01% , the lowest is CHF45.6b 2.97% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF44.3b | 8.52% |
|---|---|---|
| 2025 | CHF47.4b | 6.88% |
| 2026 | CHF48.3b | 2.08% |
| 2027 | CHF49.5b | 2.43% |
| 2028 | CHF50.6b | 2.24% |
| 2029 | CHF51.6b | 2.01% |
17 Analysts have issued an Novartis EBITDA forecast 2025. The average Novartis EBITDA estimate is CHF19.6b . This is 3.56% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF21.8b 15.11% , the lowest is CHF18.5b 2.35% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF18.8b | 3.79% |
|---|---|---|
| 2025 | CHF19.6b | 4.16% |
| 2026 | CHF20.0b | 2.22% |
| 2027 | CHF21.3b | 6.59% |
| 2028 | CHF21.9b | 2.49% |
| 2029 | CHF23.2b | 6.35% |
EBITDA Margin
| 2024 | 42.40% | 4.36% |
|---|---|---|
| 2025 | 41.32% | 2.55% |
| 2026 | 41.38% | 0.15% |
| 2027 | 43.06% | 4.06% |
| 2028 | 43.16% | 0.23% |
| 2029 | 45.00% | 4.26% |
14 Novartis Analysts have issued a net profit forecast 2025. The average Novartis net profit estimate is CHF11.6b . This is 13.12% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF13.7b 33.43% , the lowest is CHF9.5b 8.07% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF10.3b | 18.97% |
|---|---|---|
| 2025 | CHF11.6b | 13.12% |
| 2026 | CHF12.2b | 5.11% |
| 2027 | CHF12.7b | 3.94% |
| 2028 | CHF14.3b | 12.47% |
| 2029 | CHF15.1b | 5.46% |
Net Margin
| 2024 | 23.22% | 25.33% |
|---|---|---|
| 2025 | 24.58% | 5.85% |
| 2026 | 25.31% | 2.97% |
| 2027 | 25.68% | 1.46% |
| 2028 | 28.25% | 10.01% |
| 2029 | 29.21% | 3.40% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
14 Analysts have issued a Novartis forecast for earnings per share. The average Novartis <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is CHF5.89 . This is 13.05% higher than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is CHF6.95 33.40% , the lowest is CHF4.79 8.06% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF5.21 | 18.97% |
|---|---|---|
| 2025 | CHF5.89 | 13.05% |
| 2026 | CHF6.19 | 5.09% |
| 2027 | CHF6.44 | 4.04% |
| 2028 | CHF7.24 | 12.42% |
| 2029 | CHF7.64 | 5.52% |
P/E ratio
| Current | 18.83 | 36.85% |
|---|---|---|
| 2025 | 16.65 | 11.58% |
| 2026 | 15.85 | 4.80% |
| 2027 | 15.24 | 3.85% |
| 2028 | 13.55 | 11.09% |
| 2029 | 12.85 | 5.17% |
Based on analysts' sales estimates for 2025, the Novartis stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 4.44 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 4.09 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.74 | 11.27% |
|---|---|---|
| 2025 | 4.44 | 6.43% |
| 2026 | 4.35 | 2.04% |
| 2027 | 4.24 | 2.37% |
| 2028 | 4.15 | 2.19% |
| 2029 | 4.07 | 1.97% |
P/S ratio
| Current | 4.37 | 8.35% |
|---|---|---|
| 2025 | 4.09 | 6.44% |
| 2026 | 4.01 | 2.04% |
| 2027 | 3.91 | 2.37% |
| 2028 | 3.83 | 2.19% |
| 2029 | 3.75 | 1.97% |
Current Novartis Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG | Hold ➜ Hold | Unchanged | Jan 06 2025 |
| BNP PARIBAS EXANE | Neutral ➜ Neutral | Unchanged | Jan 05 2025 |
| DAY BY DAY | Buy ➜ Buy | Unchanged | Jan 05 2025 |
| GUGGENHEIM SECURITIES LLC | Neutral ➜ Neutral | Unchanged | Dec 16 2024 |
| TD COWEN | Hold ➜ Hold | Unchanged | Dec 10 2024 |
| STIFEL EUROPE | Buy ➜ Hold | Downgrade | Nov 24 2024 |
| HSBC | Hold ➜ Hold | Unchanged | Nov 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG: Hold ➜ Hold
|
Jan 06 2025 |
|
Unchanged
BNP PARIBAS EXANE: Neutral ➜ Neutral
|
Jan 05 2025 |
|
Unchanged
DAY BY DAY: Buy ➜ Buy
|
Jan 05 2025 |
|
Unchanged
GUGGENHEIM SECURITIES LLC: Neutral ➜ Neutral
|
Dec 16 2024 |
|
Unchanged
TD COWEN: Hold ➜ Hold
|
Dec 10 2024 |
|
Downgrade
STIFEL EUROPE: Buy ➜ Hold
|
Nov 24 2024 |
|
Unchanged
HSBC: Hold ➜ Hold
|
Nov 24 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
